NCT07825467Completed
Brown Adipose Tissue Activity and NAFLD Progression
A Single-Center, Non-Interventional Clinical Study Investigating the Association Between Brown Adipose Tissue Activity and NAFLD Progression
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This single-center, non-interventional observational study investigated the association between brown adipose tissue (BAT) activity and nonalcoholic fatty liver disease (NAFLD)-related clinical characteristics. Participants who had previously undergone clinically indicated 18F-FDG PET/CT examinations were enrolled. Existing PET/CT imaging data were collected and used to assess BAT activity. Peripheral blood samples were collected for plasma analysis. The study aimed to identify circulating factors associated with BAT activity and to evaluate their relationships with NAFLD-related clinical and metabolic characteristics. No additional PET/CT examination, investigational treatment, or other therapeutic intervention was performed as part of this study.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 96 (actual)
- First submitted
- 9 Sept 2026
- Start date
- 5 Jan 2026
- Primary completion date
- 5 Feb 2026
- Lead sponsor
- Renmin Hospital of Wuhan University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07825467
What you commit to
- Study type: Observational
- Participants enrolled: 96
- From 5 Jan 2026 to the primary completion date, 5 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications affecting metabolism within the previous 3 months, such as beta-blockers or thyroid hormones.
Other illness
- Contraindications to PET/CT examination, such as claustrophobia or contrast-agent allergy.
Other
- Pregnancy or breastfeeding.
Who the study is looking for
- Patients who had undergone clinically indicated 18F-FDG PET/CT examination.
- Willing and able to provide written informed consent and comply with the study procedures.
- No long-term use of medications such as glucocorticoids or lipid-lowering drugs; no smoking or excessive alcohol consumption (alcohol intake \<20 g/day).
- High BAT activity group: BAT SUVmax ≥2.0, with clear BAT activation in the cervical, shoulder, or supraclavicular regions on PET/CT.
- Intermediate BAT activity group: 1.0 ≤ BAT SUVmax \<2.0.
- Low BAT activity group: BAT SUVmax \<1.0 or no detectable BAT distribution on PET/CT.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renmin Hospital of Wuhan University Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.